SGLT2 Inhibitors Improve Cardiovascular Outcomes Across Groups - Medscape
A comprehensive meta-analysis finds cardiovascular improvement across age, sex, and race/ethnicity for high-risk individuals with type 2 diabetes and other CVD risk factors.
Sodium-glucose cotransporter 2 (SGLT2) inhibitors show "remarkable consistency of class benefit" for improving cardiovascular outcomes in high-risk people across age, sex, and race/ethnicity categori… [+4781 chars]
Read More
Other Stories in Health
- Dosa saree, Idli shirt and a pani puri watch? AI turns desi food into fashion
- Where and why men die younger: global data breaks it down
- 8 Best Foldable Rowing Machines, According to Editors and Certified Trainers
- Strawberry Lemon Cream Crepes {Grain-Free Options Included}
- What predicts belief in the afterlife? A massive global study has answers
- Getting active in midlife may boost brain resilience to Alzheimer’s
- May 2025 Cooking Challenge
- May 2025 Cooking Challenge
- TDP-43 dysfunction in brain blood vessels may drive Alzheimer's and ALS progression
.png)
